Predict your next investment

Corporation
HEALTHCARE | Drug Development
hyperiontx.com

See what CB Insights has to offer

Executives

13

Board of Directors

2

Hyperion Therapeutics Board of Directors

2 Board of directors

Hyperion Therapeutics has 2 board of directors, including Gaurav Aggarwal.

Name

Firm

Work History

Other Seats

Gaurav Aggarwal

Hyperion Therapeutics

Jake Nunn

Jake joined NEA in 2006 as a Partner. He focuses on later-stage specialty pharmaceuticals, biotechnology and medical device investments and manages a number of NEA's public investments in healthcare. Jake is a Director of Dermira (Nasdaq: DERM), Hyperion Therapeutics (Nasdaq: HPTX), Trevena, Inc. (Nasdaq: TRVN), and TriVascular (Nasdaq:TRIV). He previously was a Director of Aciex Therapeutics (sold to Nicox SA) and Transcept Pharmaceuticals (merged with Paratek Pharmaceuticals). Jake worked at MPM Capital as a Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments. Jake was also an investment banker with Alex. Brown & Sons. He received an MBA from the Stanford Graduate School of Business and an AB in Economics from Dartmouth College. Jake holds the Chartered Financial Analyst designation, and is a member of the CFA Society of San Francisco.

Hyperion Therapeutics

Name

Gaurav Aggarwal

Jake Nunn

Firm

Work History

Jake joined NEA in 2006 as a Partner. He focuses on later-stage specialty pharmaceuticals, biotechnology and medical device investments and manages a number of NEA's public investments in healthcare. Jake is a Director of Dermira (Nasdaq: DERM), Hyperion Therapeutics (Nasdaq: HPTX), Trevena, Inc. (Nasdaq: TRVN), and TriVascular (Nasdaq:TRIV). He previously was a Director of Aciex Therapeutics (sold to Nicox SA) and Transcept Pharmaceuticals (merged with Paratek Pharmaceuticals). Jake worked at MPM Capital as a Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments. Jake was also an investment banker with Alex. Brown & Sons. He received an MBA from the Stanford Graduate School of Business and an AB in Economics from Dartmouth College. Jake holds the Chartered Financial Analyst designation, and is a member of the CFA Society of San Francisco.

Other Seats

Hyperion Therapeutics

Hyperion Therapeutics

Hyperion Therapeutics Management Team

13 Team Members

Hyperion Therapeutics has 13 executives. Hyperion Therapeutics's founder is Chris Rivera. Hyperion Therapeutics's current Senior Vice President is Klara A Dickinson.

Name

Work History

Title

Status

Klara A Dickinson

Senior Vice President

Current

Christine A Nash

Senior Vice President

Current

Chris Rivera

Founder

Former

Chris Rivera

Chief Executive Officer, President

Former

Donald J. Santel

Chief Executive Officer

Former

Name

Klara A Dickinson

Christine A Nash

Chris Rivera

Chris Rivera

Donald J. Santel

Work History

Title

Senior Vice President

Senior Vice President

Founder

Chief Executive Officer, President

Chief Executive Officer

Status

Current

Current

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.